Classifications: antilipemic; hmg-coa reductase inhibitor (statin);
Therapeutic: antihyperlipemic
; statin
Prototype: Lovastatin
Pregnancy Category: X


5 mg, 10 mg, 20 mg, 40 mg tablets


Rosuvastatin is a potent inhibitor of HMG-CoA reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, an early and rate-limiting step in cholesterol biosynthesis. Interference with this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.

Therapeutic Effect

Reduces total cholesterol and LDL cholesterol; additionally, lowers plasma triglycerides and apolipoprotein B while increasing HDL.


Adjunct to diet for the reduction of LDL cholesterol and triglycerides in patients with primary hypercholesterolemia and mixed dyslipidemia.


Hypersensitivity to any component of the product, active liver disease, pregnancy (category X), women of child-bearing potential not using appropriate contraceptive measures, lactation.

Cautious Use

Concomitant use of cyclosporine and gemfibrozil; excessive alcohol use or history of liver disease; renal impairment; advanced age; hypothyroidism.

Route & Dosage

Adult: PO 10 mg once daily (5–40 mg/d), max dose 40 mg/d. If taking cyclosporine, start with 5 mg/d.
Geriatric: Initial dose of 5 mg/d

Renal Impairment
Clcr <30 mL/min: 5 mg once daily (max: 10 mg/d)


  • Persons of Asian descent may be slow metabolizers and may require half the normal dose.
  • May give any time of day without regard to food.
  • Store at or below 30° C (86° F).

Adverse Effects (≥1%)

Body as a Whole: Asthenia, back pain, flu syndrome, chest pain, infection, pain, peripheral edema. CNS: Headache, dizziness, insomnia, hypertonia, paresthesia, depression, anxiety, vertigo, neuralgia. CV: Hypertension, angina, vasodilatation, palpitations. GI: Diarrhea, dyspepsia, nausea, abdominal pain, constipation, gastroenteritis, vomiting, flatulence, gastritis. Endocrine: Diabetes. Hematologic: Anemia, ecchymosis. Musculoskeletal: Myalgia, arthritis, arthralgia, rhabdomyolysis (especially with dose >40 mg). Respiratory: Pharyngitis, rhinitis, sinusitis, bronchitis, increased cough, dyspnea, pneumonia, asthma. Skin: Rash, pruritus. Urogenital: UTI.


Drug: Cyclosporine, gemfibrozil, niacin, may increase risk of rhabdomyolysis; ANTACIDS may decrease rosuvastatin absorption; may cause increase in INR with warfarin.


Absorption: Well absorbed. Peak: 3–5 h. Metabolism: Limited metabolism in the liver (not CYP3A4). Elimination: Primarily in feces (90%). Half-Life: 20 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor for and report promptly S&S of myopathy (e.g., skeletal muscle pain, tenderness or weakness).
  • Withhold drug and notify physician if CPK levels are markedly elevated (≥10 x ULN) or if myopathy is diagnosed or suspected.
  • Lab tests: CPK levels for S&S of myopathy; periodic LFTs; more frequent INR values with concomitant warfarin therapy.
  • Monitor CV status, especially with a known history of hypertension or heart disease.
  • Monitor diabetics for loss of glycemic control.

Patient & Family Education

  • Do not take antacids within 2 h of taking this drug.
  • Females should use reliable means of contraception while taking this drug to prevent pregnancy.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

© 2006-2022 Last Updated On: 11/18/2022 (0)
Wait 20 seconds...!!!